Clinical Trials Directory

Trials / Completed

CompletedNCT01337596

A Study of LY2951742 in Healthy Volunteers

A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
63 (actual)
Sponsor
Eli Lilly and Company · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects

Conditions

Interventions

TypeNameDescription
DRUGLY2951742Administered subcutaneously
DRUGPlaceboAdministered subcutaneously

Timeline

Start date
2011-04-01
Primary completion
2012-04-01
Completion
2012-04-01
First posted
2011-04-19
Last updated
2019-02-20
Results posted
2019-02-20

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01337596. Inclusion in this directory is not an endorsement.

A Study of LY2951742 in Healthy Volunteers (NCT01337596) · Clinical Trials Directory